Interests: Cancer drug resistance; Extracellular Vesicles (EVs) as mediators of cancer drug resistance; Anticancer activity of compounds (of natural or chemical origin); Impact of the tumor microenvironment on cancer drug resistance; Molecular mechanisms for overcoming drug resistance
Special Issue Information
Several evidences have shown that the tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Indeed, the TME has been recognized as a major contributor to cancer malignancy and therapeutic resistance. The TME comprises the surrounding blood vessels, signaling molecules, the extracellular matrix (ECM) and multiple stromal cells, including cancer-associated fibroblast (CAFs), tumor-associated macrophages (TAMs), among others. The presence of these cellular components has been associated with poor prognosis and unfavorable outcomes in different types of cancers. Therefore, therapies that simultaneously target tumor cells and TME components may represent a key strategy to overcome drug resistance and improve patient outcomes. This Special Issue includes original research articles focusing on novel bioactive compounds or small molecules (chemically synthesized or of natural origin), or repurposed drugs, that target TME elements to improve cancer therapy. Review articles will also be considered.
Dr. Cristina P. R. Xavier
Manuscript Submission Information
Manuscripts should be submitted online at https://jmcm.imrpress.orgby registering and logging in to this website. Once you are registered, click here to go to the submission form.Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on theInstructions for Authorspage. Journal of Molecular and Clinical Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $500. We normally offer a discount greater than 30% for high-quality papers. Submitted papers should be well formatted and use good English.
Anticancer compounds; Cancer therapy; Repurposed drugs; Small molecules; Therapeutic resistance; Tumor microenvironment